Just like the jobs report, Cramer knows that sometimes the best investing opportunities are counterintuitive. As such is the case with Morgan Stanley, which had a major data breach this week concerning 350,000 wealth management customers.
To make matters worse, 900 customer records were posted online. As a result, investors took the stock to the wood shed.
Now, it would make sense that this data breach would be bad for business—especially for banking, since customers need to be able to trust their bank with sensitive information.
"The lesson is clear: when you're dealing with a well-run, best of breed company, any selloff caused by this kind of data breach is a reason to buy the stock," Cramer added.
One reminder as to why Cramer loves the biotech sector is the small-cap stock Agenus. This stock shot up more than 28 percent on Friday, based on the announcement of its partnership with Incyte to create cancer immunotherapy treatments.
The deal could present an opportunity to be worth as much as $350 million to Agenus, larger than the company's current market cap.
Has the jump in value been too hot for the stock? To find out, Cramer sat down with Agenus CEO Garo Armen.
"The importance of the Incyte deal is that now we have a whole spectrum of tools…their vision and capabilities allows us to get to the finish line quicker, better and more complete fashion," Armen said.
In the Lightning Round, Cramer shared other stock opportunities when he gave his take on a few caller favorites:
Cliffs Natural Resources: "No, we don't like that. Why? No offense to the guys who run it, it just happens to be a tough business. They're in the iron ore business, and it's one of the worst businesses in the world."
EV Energy Partners: "A high yield like that is a red flag. I think that the yield is probably unsustainable and therefore I think the stock could go lower."